The studies by March et al., 2019 and Takashima et al., 2019 represent the latest attempts to develop gene therapy for skin fragility diseases. Despite differences in their gene editing strategies, both groups show that programmable nucleases can be used for efficient and safe gene correction of skin cells without the use of integrating viral vectors, selection strategies, or more complex iPSC technology. One question remains: what is the best programmable nuclease for gene therapy, https://www.jidonline.org/article/S0022-202X(19)31468-X/fulltext
.png)
